Inomax
Chest Pain
National Institutes of Health Clinical Center (CC)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Chest Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Glyceryl Trinitrate National Institutes of Health Clinical Center (CC) | Phase 2 | B |
Auto-Cd34+ Cells Foundation for Biomedical Research and Innovation | Phase 1/2 | CCC |
NADOLOL Sandoz | Phase 1 | CC |
HEPARIN Nazareth Hospital | N/A | D |
Same molecule, other indications
Inomax is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →